IP Library Granted Patent US 11,420,931
Granted Patent B2
US 11,420,931 · App. 16/713,712 · Granted Aug 23, 2022

Lipid containing formulations

Inventors: Muthiah Manoharan (Cambridge, MA); Kallanthottathil G. Rajeev (Cambridge, MA); Akin Akinc (Cambridge, MA); Jayaprakash K. Nair (Cambridge, MA); Muthusamy Jayaraman (Cambridge, MA); Martin Maier (Cambridge, MA)
Assignee: ARBUTUS BIOPHARMA CORPORATION
C07C219/06A61K9/1272A61K9/1273A61K31/325C07C209/78C07C233/36C07C271/10C07C323/25A61K47/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,420,931
App. No.
16/713,712
Granted
Aug 23, 2022
Kind
B2
Abstract

Compositions and methods useful in administering nucleic acid based therapies, for example association complexes such as liposomes and lipoplexes are described.

Claims (26)

1. A lipid nanoparticle comprising a compound of formula (XV) and a therapeutic agent

wherein;

L 1 and L 2 are both bonds;

each of R 1 and R 2 is independently alkyl, alkenyl or alkynyl; each of which is optionally substituted with one or more substituents;

X is —C(O)NH—, —C(S)NH—, —C(O)C 1-3 alkylC(O)NH—; or —C(O)C 1-3 alkylC(O)O—;

m is an integer from 0-11; and n is an integer from 1-500.

2. The lipid nanoparticle of claim 1 , wherein both R 1 and R 2 are alkyl.

3. The lipid nanoparticle of claim 1 , wherein both R 1 and R 2 are alkenyl.

4. The lipid nanoparticle of claim 1 , wherein the compound of formula (XV) is a compound of formula (XV′):

5. The lipid nanoparticle of claim 1 , wherein, X is —C(O)C 1-3 alkylC(O)O—.

6. The lipid nanoparticle of claim 1 , wherein m is an integer from 1-10.

7. The lipid nanoparticle of claim 6 , wherein in is an integer from 2-4.

8. The lipid nanoparticle of claim 7 , wherein in is 2.

9. The lipid nanoparticle of claim 1 , wherein n is an integer from 1-500.

10. The lipid nanoparticle of claim 9 , wherein n is an integer from 40-400.

11. The lipid nanoparticle of claim 10 , wherein n is an integer from 40-50.

12. The lipid nanoparticle of claim 1 , wherein the compound of formula (XV) has a formula (XVI) below:

wherein the repeating PEG moiety has an average molecular weight of 2000 with n value between 42 and 47.

13. The lipid nanoparticle of claim 1 , wherein the therapeutic agent siRNA.

14. The lipid nanoparticle particle of claim 1 , wherein the therapeutic agent mRNA.

15. The lipid nanoparticle of claim 1 , wherein X is —C(O)NH—.

16. The lipid nanoparticle of claim 1 , wherein X is —C(S)NH—.

17. The lipid nanoparticle of claim 1 , wherein X is —C(O)C 1-3 alky C(O)NH—.

18. The lipid nanoparticle of claim 1 , wherein each of R 1 and R 2 is independently unsubstituted alkyl, alkenyl or alkynyl.

19. The lipid nanoparticle of claim 18 , wherein each of R 1 and R 2 is independently unsubstituted alkyl.

20. The lipid nanoparticle of claim 18 , wherein each of R 1 and R 2 is independently unsubstituted alkenyl.

Assignments (5)
SECURITY INTEREST Recorded Oct 1, 2025
From: ALNYLAM PHARMACEUTICALS, INC.; SIRNA THERAPEUTICS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 072996/0337 →
MERGER Recorded Mar 23, 2022
From: PROTIVA BIOTHERAPEUTICS, INC.
To: ARBUTUS BIOPHARMA CORPORATION
Reel/Frame 061086/0886 →
CHANGE OF NAME Recorded Mar 22, 2022
From: TEKMIRA PHARMACEUTICALS CORPORATION
To: ARBUTUS BIOPHARMA CORPORATION
Reel/Frame 059337/0845 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2021
From: ALNYLAM PHARMACEUTICALS, INC.
To: TEKMIRA PHARMACEUTICALS CORPORATION
Reel/Frame 055648/0491 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2021
From: MANOHARAN, MUTHIAH; RAJEEV, KALLANTHOTTATHIL G.; AKINC, AKIN; NAIR, JAYAPRAKASH K.; JAYARAMAN, MUTHUSAMY; MAIER, MARTIN
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 055626/0896 →
Cited By (1)
US 12,357,705